NCT00986856 is a Phase 4 clinical trial of Fucidin® cream in Impetigo, sponsored by LEO Pharma.

Who is sponsoring NCT00986856?

NCT00986856 is sponsored by LEO Pharma.

What drugs are being tested in NCT00986856?

Interventions in NCT00986856: Fucidin® cream.

Is NCT00986856 still recruiting?

NCT00986856 is currently terminated. Last updated 21 February 2025.

Are results published for NCT00986856?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-02-21 · How we verify

NCT00986856

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase IV Study Comparing Clinical and Bacteriological Efficacy of Fucidin® Cream With Fucidin® Cream Vehicle in the Treatment of Impetigo in Paediatric Patients

Terminated Phase 4 Results posted Last updated 21 February 2025

What this trial tests

Phase 4 trial testing Fucidin® cream in Impetigo in 58 participants. Terminated before completion.

Timeline

1 May 2004

Primary endpoint
1 March 2005

1 March 2005

Quick facts

Lead sponsor	LEO Pharma
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	58
Start date	1 May 2004
Primary completion	1 March 2005
Estimated completion	1 March 2005
Sites	2 locations across Norway, Sweden

Drugs / interventions tested

Fucidin® cream — full drug profile →

Conditions studied

Impetigo — all drugs for Impetigo →

Sponsor

LEO Pharma — full company profile →

Who can join

Adults 2 to 11, any sex, with Impetigo. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Patients With Clinical Success (Marked Improvement or Completely Cleared) and Bacteriological Success (Eradication) at End of Treatment (EOT).
Time frame: EOT: Visit at Day 25

Sponsor's own description

To investigate the clinical and bacteriological efficacy of Fucidin® cream in the treatment of impetigo in paediatric patients. To assess the validity of in vitro susceptibility-testing of S. aureus to fusidic acid as a prediction of clinical and bacteriological outcome in impetigo patients treated with Fucidin® cream. To investigate the genetic relationship between S. aureus-strains isolated from impetigo patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interventions for impetigo.
Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LW, et al · · 2012 · cited 59× · PMID 22258953 · DOI 10.1002/14651858.cd003261.pub3

Verify or expand the search:

Other trials of Fucidin® cream

Trials testing the same drug.

NCT03395132 — Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betametha · Phase 3 · terminated

Other LEO Pharma trials

Trials by the same sponsor.

NCT07335588 — A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus · Phase 3 · not yet recruiting
NCT07013201 — A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to · Phase 2 · recruiting
NCT06444867 — A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 15896 · Phase 1 · completed
NCT06311682 — A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and · Phase 3 · recruiting
NCT05923099 — A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic De · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00986856 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LEO Pharma
Last refreshed: 21 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00986856.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing